Neuroprotection in cerebral ischemia: Emphasis on the SAINT trial

被引：19
作者：
Chacon M.R. [1 ]
Jensen M.B. [1 ]
Sattin J.A. [1 ]
Zivin J.A. [1 ]
机构：
[1] Department of Neurosciences, University of California San Diego, La Jolla, CA 92093-0624
来源：
Current Cardiology Reports | 2008年 / 10卷 / 1期
关键词：
Cerebral Ischemia; Middle Cerebral Artery Occlusion; Acute Ischemic Stroke; Neuroprotective Agent; Nalmefene;
D O I：
10.1007/s11886-008-0008-2
中图分类号：
学科分类号：
摘要：
Acute ischemic stroke (AIS) is a significant cause of death and disability in the United States. It has been 10 years since tissue plasminogen activator became the first medication approved by the US Food and Drug Administration for treatment for AIS. However, this treatment simply reopens arteries. The identification of deleterious cellular reactions that occur secondary to cerebral ischemia has led investigators to search for neuroprotection strategies to complement reperfusion. More than 100 human trials, including a handful of phase III trials, had failed to produce an efficacious neuroprotective agent. In 2006, the first positive trial of neuroprotection was published: the SAINT I (Stroke-Acute Ischemic NXY Treatment) study. In February 2008, the SAINT II study was published, indicating that NXY-059 was not effective for AIS treatment. © Current Medicine Group LLC 2008.
引用
收藏
页码：37 / 42
页数：5
相关论文
共 56 条
[1]  
Thom T., Haase N., Rosamond W., Et al., Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 113, (2006)
[2]  
Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, 333, pp. 1581-1587, (1995)
[3]  
Lyden P., Wahlgren N.G., Mechanisms of action of neuroprotectants in stroke, J Stroke Cerebrovasc Dis, 9, pp. 9-14, (2000)
[4]  
O'Collins V.E., Macleod M.R., Donnan G.A., Et al., 1,026 experimental treatments in acute stroke, Ann Neurol, 59, pp. 467-477, (2006)
[5]  
Kidwell C.S., Liebeskind D.S., Starkman S., Saver J.L., Trends in acute ischemic stroke trials through the 20th century, Stroke, 32, pp. 1349-1359, (2001)
[6]  
Lees K.R., Zivin J.A., Ashwood T., Et al., NXY-059 for acute ischemic. stroke, N Engl J Med, 354, pp. 588-600, (2006)
[7]  
Labiche L.A., Grotta J.C., Clinical trials for cytoprotection in stroke, NeuroRx, 1, pp. 46-70, (2004)
[8]  
Davis S.M., Lees K.R., Albers G.W., Et al., Selfotel in acute ischemic stroke: Possibleneurotoxic effects of an NMDA antagonist, Stroke, 31, pp. 347-354, (2000)
[9]  
Albers G.W., Goldstein L.B., Hall D., Lesko L.M., Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial, JAMA, 286, pp. 2673-2682, (2001)
[10]  
Lees K.R., Asplund K., Carolei A., Et al., Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. GAIN International Investigators, Lancet, 355, pp. 1949-1954, (2000)
123456